

**CSHP Professional Practice Conference 2011: Poster Abstracts / Conférence sur la pratique professionnelle 2011 de la SCHP : Résumés des affiches**

**Sunday, January 30, 2011 • Dimanche 30 janvier 2011**

**Infectious Disease**

1. Evaluation of Clinical and Economic Outcomes of Alternative Meropenem Dosing Compared to Traditional Dosing
2. A Quality Audit of the Surgical Antibiotic Prophylaxis at a Tertiary Care Hospital
3. A Reliable Method of Obtaining Blood Samples from Implantable Central Venous Catheters for Determination of Plasma Gentamicin Concentrations
4. Single versus Double Gram Negative Coverage Empiric Antibiotic Therapy of Febrile Neutropenia in Pediatric Patients
5. Development of a Novel Vancomycin Dosing Nomogram for Achieving High-Target Pre-Dose Levels at Two Major Canadian Teaching Hospitals
6. Evaluation of Dosing Strategies with Meropenem Using Monte Carlo Simulation to Determine the Probability of Attaining Pharmacokinetic-Pharmacodynamic Targets in a Model of Critically Ill Patients with *Pseudomonas aeruginosa* Bacteremia

**Drug Use/Primary Care**

7. Drugs Use among Seniors on Public Drug Programs in Canada, 2002 to 2008
8. Adherence Measurement Methods among HIV Positive Adolescents in Uganda: A Prospective Cohort Study
9. Retrospective Review of Phenytoin Utilization in Traumatic Brain Injury at The Ottawa Hospital, Civic Campus
10. Optimising Medications in Older People with Cognitive Impairment Presenting to a Family Health Team Based Memory Clinic
11. Development and Evaluation of an Instrument for the Critical Appraisal of Randomized Controlled Trials of Natural Products
12. Pharmacists Adapting to Change: The Who’s Who of the Pilot Cohort of an E-Learning Primary Health Care Program

**Medication Safety**

13. Medication Error Reporting: A Qualitative Analysis of Incentives, Barriers, and Facilitators as Perceived by Health Care Professionals in Nova Scotia
14. Medication Incidents Involving Psychotropic Drugs: An Aggregate Analysis
15. Failure Mode Effects Analysis (FMEA) for Morphine Prescribing Practices
16. Can a Pharmacy Student-Pharmacist Model Be Used to Overcome Challenges and Sustain Admission Reconciliation?
17. Pharmacy Improving Patient Safety: A Retrospective Analysis
18. Adverse Events Identified in a Canadian Pediatric Teaching Hospital

**Cardiology/Critical Care/Transplant**

19. Description of Vitamin K Use for Reversing Anticoagulation on Inpatient General Medicine Units
20. Development of a Home Intravenous Inotrope Program for End-Stage Heart Failure Patients
21. An Analysis of QTc Prolongation 
22. Development and Validation of Limited Sampling Strategies for Tacrolimus and Mycophenolate in Steroid-Free Renal Transplant Regimens
23. Effectiveness and Safety of an Electrolyte Replacement Protocol in Critical Care Settings
24. Antimicrobial Use in a Critical Care Unit: A Prospective Observational Study

---

The texts of poster abstracts are published exactly as submitted by the authors and have not undergone any copyediting by the Canadian Journal of Hospital Pharmacy.

*Le Journal canadien de la pharmacie hospitalière n’a pas soumis le texte des résumés des affiches à une révision linguistique et les public ici tels que remis par les auteurs.*

---

**Monday, January 31, 2011 • Lundi 31 janvier 2011**

1. Mood Elevation and Pain Control with Duloxetine Monotherapy in Multiple Sclerosis
2. Drug Related Problems in the Elderly Attending a Geriatric Day Hospital
4. Medical, Medication and Lab Error in Eight Countries: Self-Reported Risk Factors for Sicker Adults
5. Risk Factors for Self-Reported Medication Errors in the Hospital and Community Settings in Eight Countries
6. Adverse Events Related to Medications Identified by a Canadian Poison Centre
7. Evaluation of the Efficacy and Toxicity of Once Daily Gentamicin for Febrile Neutropenia in Pediatric Oncology Patients
8. Optimization of Medication Reconciliation on Admission for Pediatric Inpatients

---

**Tuesday, February 1, 2011 • Mardi 1er février 2011**

1. Étude pilote sur la surveillance environnementale en pharmacie communautaire
2. Sommes-nous prêts à partager les données du dossier pharmacologique informatisé des patients hospitalisés?
3. Perspective des ruptures d’approvisionnement de médicaments 2004-2010
4. Développement d’une approche web peu coûteuse pour la formation continue intra-hospitalière
5. Impact of a Debate on Pharmacy Students’ Views of Online Pharmacy Practice
6. Projet AMÉLIE : Analyse des modes de défaillance, de leurs effets et de leur criticité: un modèle pour évaluer le circuit du médicament des infirmières à l’étage
7. Development of a Diary for Use by Children to Record their Chemotherapy-Induced Nausea and Vomiting Experience
8. Evolution of Prescription Patterns for Acute Otitis Media in Children at the Emergency Department

---

**Wednesday, February 2, 2011 • Mercredi 2 février 2011**

1. Point Prevalence Survey of Antimicrobial Utilization in the Cardiac and Paediatric Critical Care Unit
2. St-Michael’s Pharmacists Academy of Learning Pilot Program: An Educational Model for Training and Assessment of New Pharmacists and Interns
3. Medication Incidents Involving Cancer Chemotherapy Agents
4. Identification of Medication Safety Indicators in Acute Care Settings for Public Reporting in Ontario
5. Sustained Cost Savings and Fewer Dose Administration Errors in Hemodialysis Patients Converted from Epoetin Alfa to Darbepoetin Alfa in a Community Hospital Setting
6. Revising Automated Dispensing Cabinet Inventory to Improve Efficiency
7. Early Impact of a Decentralized Automated Dispensing System in a Small Regional Hospital
Evaluation of Clinical and Economic Outcomes of Alternative Meropenem Dosing Compared to Traditional Dosing

Shazia Syed, Annie Brooks, Melani Sung
Hamilton Health Sciences, West, Hamilton, ON

Objective: To compare clinical and economic outcomes in patients receiving traditional meropenem dosing (1 g Q8H) with alternative dosing (500 mg Q6H) before and after the implementation of an autosubstitution policy based on pharmacodynamic evidence of equivalence.

Methods: A retrospective chart review of patients prescribed meropenem 5 months prior to (September 2008-February 2009) and 5 months after the implementation of the autosubstitution policy (February-July 2009) for P&T committee approved indications was conducted. Clinical outcomes of proportion of patients afebrile at 72 hours, time to defervescence and clinical failure rate were assessed. A cost minimization analysis was completed to quantify any cost savings accrued through implementation of the policy.

Results: 28 patients who received meropenem 1 g Q8H and 29 who received 500 mg Q6H met our inclusion criteria. No significant differences in baseline demographics, indication for meropenem use, duration of therapy, and concomitant antibiotic use were observed between groups. The proportion of patients afebrile at 72 hours (61% vs. 79%, p=0.15) and clinical failure rate (39% vs. 24%, p=0.26) was not statistically significantly different in the traditional and alternative dosing regimen, respectively. Of the 9 patients in each treatment group who were febrile upon initiation of therapy, mean time to defervescence did not differ significantly (traditional dosing: 134.4 h, alternative dosing: 89.3 h, p=0.33). Cost minimization analysis revealed significant cost savings as quantified by mean cost per patient ($1262.45 vs. $849.78, p=0.02) and total drug acquisition cost associated expenditure ($49235.70 vs. $43489.10, p=0.02) in the traditional and alternative dosing groups, respectively.

Conclusion: The pharmacodynamically optimized alternative dosing regimen of meropenem revealed similar clinical outcomes with significant economic benefits compared to the traditional dosing in the 5 month pre and post implementation period of the autosubstitution policy.

A Quality Audit of the Surgical Antibiotic Prophylaxis at a Tertiary Care Hospital

Monique M Pitre, Gary G Wong, James Murdoch, Sophia Cao, Baseer Yasseen
Department of Pharmacy Services, University Health Network, Toronto, ON

Background: Antibiotic prophylaxis is uniformly recommended for all clean-contaminated, contaminated and dirty procedures. The type, dosing and timing of antibiotic administration is critical to its efficacy in reducing surgical infections. The purpose of this audit was to evaluate the compliance with the pre-, intra-, and post-operative recommendations for antibiotic prophylaxis at a tertiary care hospital.

Method: A retrospective chart review was conducted using standardized data forms. Data was collected on 528 surgeries over two weeks in May/June 2009. Ninety-two surgeries were excluded (76 cancelled, 2 missing data, 14 transplantations). Data was collected from the pre-, intra-, and post-operative period. Compliance with recommendations was defined as appropriate antibiotic selection, dose and timing at each stage of surgery (pre-, intra- and post-operative). Data was recorded in a database and analyzed using SPSS v17.0.

Results: The pre-operative antibiotic dose was administered in 84.6% (n=447) of the surgeries and compliance with guideline was 66.9% (n=353). Gynecology-oncology (Gyn-Onc) surgeries were the highest at 85.7% (n=18) and urological surgeries were lowest at 22% (n=9). The intra-operative compliance with guidelines was 93.9% (n=436). The post-operative compliance with guidelines was 69.1% (n=365). Compliance was the highest in Gyn-Onc surgeries at 90.5% (n=19) and lowest in vascular surgeries at 35.0% (n=7). The overall compliance with antibiotic prophylaxis at University Health Network was 46.2% (n=244). Gyn-Onc surgeries were highest at 76.2% (n=16) and urological surgeries were lowest at 17.0% (n=7).

Conclusion: More than half the surgeries (53.8%, n=284) were not fully compliant with all aspects of the guideline. Non-compliance was a result of inappropriate antibiotic selection, antibiotic dose and (or) timing of antibiotic administration. Further analysis is planned to determine the most common predictors of non-compliance.

A Reliable Method of Obtaining Blood Samples from Implantable Central Venous Catheters for Determination of Plasma Gentamicin Concentrations

Jennifer Chen, Sabrina Boodhun, Sara Rosaline Lavatore, I. Lee Dupuis
The Hospital for Sick Children, Toronto, ON

Background: Obtaining blood samples from children is an activity which impacts patients, families and caregivers daily. In children with cancer, blood samples are routinely drawn from subcutaneous central venous catheters (ports) using the discard method, finger lancet punctures (FLPs) or venipunctures to determine the plasma gentamicin concentrations (PGCs) required to individualize gentamicin dosing. However, the discard sampling method produces unreliable results and contributes to iatrogenic blood loss while FLPs/venipunctures are painful. Alternative methods of sampling are needed.

Objective: This study evaluated the extent of agreement between PGCs determined in samples obtained via ports using the push-pull method and FLPs in children with febrile neutropenia.

Methods: Children with cancer with single or double-lumen ports who were receiving gentamicin participated in this prospective study. PGCs were determined in blood samples obtained via the port using the push-pull method and via FLP Agreement between PGCs determined in port and FLP blood samples was assessed by the intraclass correlation coefficient (ICC), Bland-Altman analysis and comparison of simulated dose adjustments. Changes in port patency were tracked for 1 week following port sampling. The acceptable targets for the lower limit of the ICC and Bland-Altman limits of agreement were ≥ 0.80 and ±6%, respectively. Differences in simulated dose adjustments calculated using either the port or FLP samples that differed by > 20% were considered to be clinically significant.

Results: Agreement between the 44 FLP and port sample pairs collected was excellent (ICC: 0.991; 0.984 to 0.995). Port PGCs were 4.7% lower than PGCs determined in FLP samples. The observed limits of agreement were -20.5% to 11%. Differences in dose adjustments calculated using port and FLP PGCs were clinically insignificant in the majority (88.4%) of cases. No changes in port patency were observed in the week following the port sample.

Conclusion: The push-pull method of blood sampling is a reliable and safe option for obtaining PGC results in children with ports.
Single versus Double Gram Negative Coverage Empiric Antibiotic Therapy of Febrile Neutropenia in Pediatric Patients

Shane Pawluk, Roberta Eatsu, Claire Aston, Rod Rasekh, Roxane Carr

BC Children’s Hospital, Vancouver, BC

Rationale: In adult patient with febrile neutropenia, there is no difference in efficacy between single and double gram negative coverage antibiotic regimens. Outcomes of these different antibiotic regimens have not been assessed in the pediatric population.

Objectives: To compare the effectiveness and safety of a double coverage gram negative antibiotic regimen to a single coverage gram negative antibiotic regimen in pediatric febrile neutropenia patients.

Methods: Retrospective review of patients who received piperacillin-tazobactam with or without gentamicin. Data collected using a standardized data collection form. Wilcoxon Rank-Sum Test was used to compare duration of fever and change in serum creatinine between the two treatment groups.

Results: A total of 60 patients were included in this study. Mean duration of fever was 3.5 days in the double coverage group and 3.1 days in the single coverage group (p = 0.5). Addition of vancomycin was similar in double and single coverage groups (16.7% vs. 13.3%). Addition of gram negative coverage antibiotics occurred more frequently in the single coverage group. Mean percent increase in serum creatinine was 25% in the double coverage group and 10% in the single coverage group (p = 0.03).

Conclusion: A similar duration of fever was observed in both treatment groups. The single coverage group received additional gram negative antibiotics more frequently than the double coverage group. Although statistically significant, the change in serum creatinine in the double gram negative coverage group compared to the single coverage group was not clinically significant.

Development of a Novel Vancomycin Dosing Nomogram for Achieving High-Target Pre-Dose Levels at Two Major Canadian Teaching Hospitals

Rosanne Thalakada¹, Tim T Y Lau¹, Michael Lega², Joshua Batterink³, Mary H H Eunom⁴

¹Vancouver General Hospital, Vancouver, BC
²St. Paul’s Hospital, Vancouver, BC
³Vancouver Coastal Health–Providence Health Care, Vancouver, BC
⁴Children’s and Women’s Health Centre of British Columbia, Vancouver, BC

Rationale: Recent clinical practice guidelines now recommend a target vancomycin pre-dose level of 15-20 mg/L for invasive infections. Most existing nomograms are designed to achieve lower targets (5-15 mg/L). There is a need for validated nomograms to achieve high target pre-dose levels of 15-20 mg/L.

Objectives: To develop and validate an initial vancomycin dosing nomogram to achieve pre-dose levels of 15-20 mg/L at St. Paul’s Hospital and Vancouver General Hospital.

Methods: This was a retrospective study conducted at St. Paul’s Hospital and Vancouver General Hospital. Patients who had achieved a pre-dose vancomycin level of 15-20 mg/L were identified. Patient demographics and relevant clinical data were collected. Multiple linear regression was used to develop a vancomycin dosing nomogram at each site. An integrated nomogram was constructed by merging the data from both hospitals. The nomograms were validated in unique sets of patients at each institution. Predictive success of each nomogram was deemed significantly different from another nomogram if p<0.05 via Chi-square test.

Results: Sixty-eight patients were used for St. Paul’s Hospital nomogram development and 78 patients were used for Vancouver General Hospital’s nomogram development. Both age and serum creatinine had a significant effect on the predicted dosage interval (p<0.001). Validation in a total of 80 test patients showed that the integrated nomogram had the highest predictive success in the St. Paul’s Hospital test group and the second highest success in the Vancouver General Hospital group with 66% and 64% correctly predicted intervals, respectively (p<0.005).

Conclusion: A novel vancomycin dosing nomogram has been developed and successfully validated at two major Canadian teaching hospitals. This integrated nomogram will assist clinicians in selecting appropriate initial vancomycin regimens using age and serum creatinine to achieve high target levels of 15-20 mg/L. Expansion of the nomogram to include patients with impaired renal function in addition to prospective evaluation of the nomogram is underway.

Evaluation of Dosing Strategies with Meropenem Using Monte Carlo Simulation to Determine the Probability of Attaining Pharmacokinetic-Pharmacodynamic Targets in a Model of Critically Ill Patients with Pseudomonas aeruginosa Bacteremia

Miranda Se¹, Scott E. Walker¹, Sandra A N Walker¹²

¹Leslie Dan Faculty of Pharmacy, University of Toronto, ON
²Sunnybrook Health Sciences Centre, Toronto, ON

Rationale: For meropenem, maintaining time above minimum inhibitory concentration (MIC) relative to dosing interval (%T>MIC) at ≥40% may improve clinical outcome. Monte Carlo Simulations (MCS) using pharmacokinetic parameters of healthy subjects showed that prolonged infusion (PI) (≥3 hours) improved probability of target attainment (pTA) over short infusion (SI). PI’s role in the critically ill is less clear.

Objectives: To develop a meropenem dosing strategy for critically ill patients against a distribution of P. aeruginosa MICs reported at Sunnybrook Health Sciences Centre (SB) between 2002 and 2009. Methods: Summarized meropenem pharmacokinetic parameters (weighted mean ± standard deviation) of healthy volunteers (N=146) and the critically ill (N=98; CrCl≥40mL/min) extracted from a literature search were used to build their respective models. %T>MIC was calculated by [(T>MIC during infusion + T>MIC post-infusion)/dosing interval] x 100. One million MCSs were generated with Crystal Ball v. 11.1.1.3.00 using permutations of dosage (500, 1000 and 2000 mg); frequency (Q8H; Q6H); and infusion time (SI=0.5 and PI=3 hours). A successful regimen would guarantee pTA ≥90%.

Results: Pharmacokinetic parameters used in MCS:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Healthy Subjects</th>
<th>Critically Ill</th>
<th>P-value (unpaired t-test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clearance (L/hr)</td>
<td>14.24±2.819</td>
<td>8.73±5.044</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Half-life (hr)</td>
<td>0.88±0.2687</td>
<td>2.81±1.009</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Volume of</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution (L)</td>
<td>16.34±3.072</td>
<td>21.11±6.101</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
pTA according to highest MIC (mcg/mL) against which regimen is successful:

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Healthy Subjects</th>
<th>Critically Ill</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MIC (mcg/mL)</td>
<td>pTA (%)</td>
</tr>
<tr>
<td>500 mg Q6H SI</td>
<td>2</td>
<td>97.7</td>
</tr>
<tr>
<td>500 mg Q6H PI</td>
<td>4</td>
<td>99.6</td>
</tr>
<tr>
<td>1000 mg Q8H SI</td>
<td>2</td>
<td>93.2</td>
</tr>
<tr>
<td>1000 mg Q8H PI</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>1000 mg Q6H SI</td>
<td>4</td>
<td>97.7</td>
</tr>
<tr>
<td>1000 mg Q6H PI</td>
<td>8</td>
<td>99.6</td>
</tr>
<tr>
<td>2000 mg Q8H SI</td>
<td>4</td>
<td>93.2</td>
</tr>
<tr>
<td>2000 mg Q8H PI</td>
<td>8</td>
<td>100</td>
</tr>
<tr>
<td>2000 mg Q6H PI</td>
<td>16</td>
<td>89.9</td>
</tr>
</tbody>
</table>

Approximately 70% of our Pseudomonas isolates had MIC of 8-16 mcg/mL. The only dosing regimen that met target %T>MIC with near 90% (89.6%) probability at MIC 16 mcg/mL was 2000mg Q8H PI.

Conclusion: For critically ill patients with suspected *P. aeruginosa* bacteremia having multi-drug resistance that necessitates optimization of available therapies, such as meropenem, MIC testing is recommended to determine whether alternative dosing of meropenem at 2000 mg Q8H infused over 3 hours is justified.

---

**Drugs Use among Seniors on Public Drug Programs in Canada, 2002 to 2008**

*M Gaucher, J Hunt*  
Canadian Institute for Health Information, Ottawa, ON

**Rationale:** The use of multiple medications can increase the risk of adverse effects, drug interactions and non-compliance with drug therapy, all of which may result in less-than-optimal health outcomes. Seniors are at a particularly high risk of adverse effects. Although it may be appropriate for a patient to be taking a high number of medications, the additional risks should be considered.

**Objective:** To examine the number and types of drugs being used by seniors, and how utilization changes as seniors age.

**Methods:** This study examined claims for 1,039,642 seniors on public drug programs in Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia and PEI from 2002 to 2008, representing over 80% of the senior population in those provinces in 2008. Drug classes were defined using the World Health Organization’s Anatomical Therapeutic Chemical classifications. The number of drugs was calculated as the number of unique drug classes a person claimed in a given year.

**Results:** In 2008, 21.4% of seniors on public drug programs had claims for 10 or more drug classes, a slight increase from 2002 (18.6%). The number of drug classes used by seniors increased with age. The most commonly used drug classes were used to treat chronic conditions such as high cholesterol, high blood pressure, heart failure, and emphysema. 3-hydroxy-3-methyl-glutaryl-Coenzym A reductase inhibitors were the most commonly used drug class among seniors aged 65 to 84, while single-ingredient angiotensin-converting enzyme inhibitors were the most commonly used class among those aged 85 and over.

**Conclusions:** Findings suggest a high proportion of seniors may be at risk for drug interactions and other adverse events due to the number of medications they are taking. This illustrates the importance of medication management strategies for seniors, and the need for communication between health care providers regarding seniors’ drug regimens.

---

**Adherence Measurement Methods among HIV Positive Adolescents in Uganda: A Prospective Cohort Study**

*Matthew O Wiest 1, Stuart MacLeod 2, Victor Musimu 2, Mark Senyonga 2, Ruth Kizza 3, Sabrina Kitaka 4, Richard Odai Adeome 4, Francis Ssali 5*  

1University of British Columbia, Vancouver, BC  
2Child and Family Research Institute, Vancouver, BC  
3Joint Clinical Research Centre, Kampala, Uganda  
4Norna Stockholms Psykiatr, S Göran Hospital, Stockholm, Sweden  
5Makerere University, Kampala, Uganda

**Rationale:** Adherence to antiretroviral is important to mitigate resistance and adolescents are considered to be high-risk for poor adherence. Innovative methodology is required to assess this issue in Uganda.

**Objective:** To determine the feasibility of a large-scale and long-term adherence study using electronic monitoring in an adolescent HIV-positive population in Uganda and to compare accuracy of pill count (PC) and self report (SR) adherence determination with adherence determination using electronic medication vials (eCAPs).

**Design and Methods:** Adolescents were recruited at the Joint Clinical Research Centre in Kampala, Uganda. All antiretrovirals were dispensed in eCAPs for 1 year. Data was downloaded during refills and PC/SR adherence was determined. Person-pill-days (one day where adherence was measured for one medication in one person) was calculated for each patient and a weighted paired t-test was then used to compare the levels of adherence among all subjects for the three different adherence methods.

**Results:** Fifteen patients were included: 40% were female, the mean age was 14, the mean baseline CD4 count was 244, and average treatment duration was 9 months prior to study entry. They provided a total number of 4721 person-pill-days. Several eCAPs required replacement during the study resulting in some data loss. Compliance for SR was 99%, PC was 97% and eCAP was 88%. Weighted difference between eCAP and SR was 12.1% (95%CI 6.7%-17.6%), between eCAP and PC was 10.4% (95%CI 4.3%-16.5%), and between SR and PC was 1.7% (95%CI 0.3%-3.1%). 93%, 67% and 23% of patients had a measured compliance of greater than 95% among SR, PC and eCAP methods, respectively.

**Conclusions:** A large-scale adherence study in Uganda is feasible using a more robust electronic monitoring system. Adherence measurements produced by pill counts and self reporting methods appear to overestimate adherence measured electronically. However, overall adherence measured with all methods was still clinically acceptable.

---

**Retrospective Review of Phenytoin Utilization in Traumatic Brain Injury at The Ottawa Hospital, Civic Campus**

*Michelle Pittman, Alexander Kuo, David Neilipovitz, Robert MacLean*  
The Ottawa Hospital, Ottawa, ON

**Rationale:** Published guidelines for traumatic brain injured (TBI) patients include routine phenytoin prophylaxis for post-traumatic seizures (PTS).

**Objectives:** The incidence of PTS, potential drug interactions, rates of adverse drug reactions (ADR), and actual phenytoin utilization following TBI at The Ottawa Hospital (TOH) was unknown, therefore this project aimed to characterize these aspects of TBI.

**Study Design and Methods:** A retrospective chart review of the last 200 patients admitted with TBI. Data were collected for the first 7 days of admission (or until discharge if earlier) and included demographics, loading (LD) and maintenance (MD) phenytoin dosing parameters,
Optimising Medications in Older People with Cognitive Impairment Presenting to a Family Health Team Based Memory Clinic

Tejal Patel1, Carlos Rojas-Fernandez1, Mina Mikhail1, Linda Lee2,3
1University of Waterloo School of Pharmacy, Waterloo, ON
2Centre for Family Medicine Family Health Team, Kitchener, ON
3Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON

Background and Rational: Pharmacotherapeutic problems (PTPs) are common in older people and can result in significant morbidity and mortality. These problems are magnified among those with cognitive impairment and/or dementia, who are highly susceptible to drug induced cognitive and functional impairment. The Memory Clinic at the Centre for Family Medicine Family Health Team is a novel, primary-care based, inter-professional clinic for patients with cognitive impairment that includes a clinical pharmacist as part of the team. There is a paucity of literature regarding the types of PTPs that burden these patients and that may be identified and managed by a clinical pharmacist.

Objectives and Methods: The objectives of this study are to describe: 1) The types of PTPs present in patients who present to the clinic, and 2) medication assessment activities of the pharmacist. Charts of 20 patients who were assessed between July 28-Sept 28th, 2010 were reviewed for demographic data, diagnoses, medications, and care plans. Pharmacotherapy problems were categorized using Carter et al’s taxonomy.

Results: There were 14 females and 6 males (mean age 75 years old). Diagnoses were (some had >1 diagnosis): mild cognitive impairment (n=5), Alzheimer’s Disease (n=3), Dementia with Lewy Bodies (n=1), mixed dementia (n=6), depression (n=6), and no cognitive impairment (n=3). Pharmacotherapeutic interventions were necessary for most (95%) patients and consisted of discontinuing anticholinergic drugs (10%), medications without an indication (30%), untreated conditions (20%), and undertreated conditions (45%). Forty-two separate recommendations were made. The most frequent were initiating medications (21%), a change in dose (13%), discontinuing medications or switching to alternative medications (12% each), provide patient education (12%), and enhance adherence (10%).

Conclusions: PTPs are common in older people with cognitive impairment or dementia, can be readily identified and managed by a clinical pharmacist. These interventions are key in optimising the care of these vulnerable patients.
Rationale: The ADapting pharmacists’ skills and Approaches to maximize Patient’s drug Therapy effectiveness (ADAPT) blended e-learning and experiential program (being piloted across Canada) aims to help pharmacists integrate professional skills required for collaborative patient care into everyday practice. Understanding the pilot participants helps with understanding other results of the program evaluation.

Objectives: To describe the demographics of the ADAPT pilot cohort, their preparedness and motivation levels and reasons for participating.

Study Design and Methods: The ADAPT evaluation is a multi-component, mixed-methods assessment. This component captured demographic information, preparedness and motivation levels (analyzed with descriptive statistics). Qualitative analysis of introductory posts included deductive and inductive methods to identify themes. The research team held iterative discussions.

Results: Eighty-six pharmacists began the program (72% female, average age 40, age range 21-62). Practice sites include community pharmacy only (46.5%), family practice only (5.8%), hospital pharmacist only (11.6%), ambulatory care clinic only (7%) combinations of practice settings (26.7%) and other (2.3%). Participants regularly engage in ongoing education, many possessing additional certifications. Preparedness was high as nearly all participants (99%) stated having 4+ hours/week for the program and 77% having 2+ hours/week for patient interaction. Most participants had a private or semi-private space for patient interaction (69%). Ninety-six percent of participants were highly motivated to improve their skills. Qualitative data revealed participants wanted to improve their skills to provide better patient care and to prepare them for changes in the profession, including working within an interprofessional team. Participants described varied experience participating in on-line learning.

Conclusion: The pilot cohort of ADAPT participants represents both new and experienced practitioners with varied backgrounds. They recognize the need for change and are motivated to engage in ongoing education to seek skills to adapt to change and improve patient care.

Medication Error Reporting: A Qualitative Analysis of Incentives, Barriers, and Facilitators as Perceived by Health Care Professionals in Nova Scotia
Nicole R Hartnell, Neil J MacKinnon, Ingrid Skeetris, Steven M Smith, Mark Fleming

Rationale: Opportunities to improve patient safety are hindered by wide-spread under-reporting of medication errors. Data from these reports can be used to improve processes, identify areas for progress, and prevent similar errors from occurring in other settings.

Objectives: (1) to identify incentives, barriers and facilitators to medication error reporting, as perceived by front-line health care professionals, and (2) to understand why certain factors serve as barriers and to explore what some hospitals have done to successfully break down barriers.

Study Design and Methods: A comparative case study analysis of medication error reporting practices and beliefs at four community hospitals in Nova Scotia was completed using focus groups (with physicians, pharmacists, and nurses) and in-depth interviews (with risk managers). Focus groups and interviews were audio taped, transcribed verbatim, and analyzed for themes using the template style of analysis. Safety Culture Theory was used to develop and analyze this study.

Results: Careful analysis of the textual data identified themes related to incentives for, barriers to, and positive facilitators of medication error reporting. Incentives were thematized into three categories: patient protection, provider protection, and professional compliance. Barriers were thematized into five categories: reporter burden, professional identity, information gap, organizational factors, and fear. Positive facilitators were thematized into three categories: reducing reporter burden, closing the communication gap, and educating for success. Participants indicated they would report medication errors more frequently if reporting were made easier and if educated about the reporting process and timely feedback.

Conclusion: These results could be used by hospitals to encourage reporting of medication errors and ultimately make organizational changes leading to a reduction in the incidence of medication errors and an improvement in patient safety. Future research efforts should focus on evaluating the effectiveness of implementing various strategies suggested for improving medication error reporting.

Medication Incidents Involving Psychotropic Drugs: An Aggregate Analysis
Roger Cheng, Calvin Poon, Sanaz Riahi, Sylvia Hyland
Institute for Safe Medication Practices Canada, Toronto, ON

Rationale: Mental health disorders pose a significant burden to the Canadian healthcare system, both from an epidemiological and financial perspective. Given the prevalence and financial burden of treating mental disorders, it is imperative that there is a strong emphasis on safe medication practices when managing psychotropic medications. By analyzing the incidents involving psychotropic medications, systems based contributing factors could be identified which can inform quality improvement initiatives.

Description and Steps Taken: Medication incidents from the ISMP Canada database were collected from October 7, 2000 to July 29, 2009. Incidents with an outcome of harm or death involving antipsychotics, antidepressants, antianxiety agents, sedatives and hypnotics were included. A quantitative analysis was conducted to provide an overview of various trends such as the severity of outcome. A qualitative analysis was conducted to identify recurrent themes and contributing factors.

Evaluation: A total of 88 incidents were included in the analysis; 82 had an outcome of harm, and 6 had an outcome of death. These incidents occur at different patient care settings including the hospital, community pharmacy and long term care. A number of themes have been identified and were classified under the patient care setting where the incident occurred. For example, in the hospital setting, the themes identified included “multiple medications”, “incorrect dose”, “incorrect patient”, “incorrect medication”, “change in order”, “transitions of care” and “dose omission”. Incidents classified under these themes were further analyzed to identify potential contributing factors. Examples of contributing factors identified included complicated instructions in orders, pre-pouring of medications and the lack of a systematic medication reconciliation process.

Importance: The results of this analysis can provide insights into areas for system improvements for the use of psychotropic medications. The potential contributing factors identified provide a solid foundation for the development of solutions to minimize the recurrence of similar incidents.
Difficulty in identifying patients requiring a BPMH (2) efficiently tracking completed BPMHs with a paper-based recording system and 3) competing pharmacist workload priorities limiting time for reconciliation. Overall, 470 patients were admitted to inpatient units over the course of 11 weeks of observation in 2010. Pharmacists and students worked together to achieve and sustain BPMH and reconciliation activities for admitted patients (80%) target for admitted patients receiving reconciliation was reached by day 12, compared to 40% at baseline without the student model, and sustained over study period with > 84% over the last 8/11 weeks).

Importance: A collaborative model was developed that optimally facilitated an effective process of students (conducting BPMHs) supporting pharmacists in achieving target patient admission reconciliation. We believe a similar model can successfully aid other hospitals having challenges sustaining reconciliation, while providing students with the opportunity to actively learn and engage in essential direct patient care.
Adverse Events Identified in a Canadian Pediatric Teaching Hospital
Stacy Ackroyd-Solarz1, Ferne Mardlin-Smith1, Darlene Bolivar1, Neil MacKinnon2, Mary-Anne Hiltz2
1Department of Emergency Medicine, Queen Elizabeth II Health Sciences Centre, Halifax, NS
2IWK Health Centre, Halifax, NS

Rationale: Voluntary reporting systems for adverse events (AEs) are commonly used despite the evidence that a significant proportion of events go unreported. Other approaches capitalize on existing administrative data to identify harm.

Objective: To demonstrate the feasibility of using routinely collected administrative data to identify AEs in outpatients and inpatients at a one Canadian pediatric teaching hospital.

Study Design and Methods: This retrospective cross-sectional pilot study was conducted at the IWK Health Centre from April 1, 2008–March 31, 2009. The primary outcome measure was the occurrence of an AE identified from electronic administrative data using validated screening criteria (sensitivity 59.9%, 95% CI 42.8-75.0; specificity 97.4%, 95% CI 94.1-98.8).

Results: There were a total of 2,333 AEs coded in 1,179 (2.4%) of the 49,234 eligible patient registrations. Approximately 68% of registrations were for outpatient services (including the emergency department and day surgery); the remaining 32% were for inpatient admissions. The most common types of AEs were procedure-related (1,299 [58.3% of 2,333]), medication-related (615 [26.4%]) and those related to devices, implants or grafts (415 [17.8%]). Those with an AE were significantly older (15.4 vs. 9.9 years, P<0.0001), more likely to be admitted to a pediatric intensive care unit (5.3% vs. 2.3%, P<0.0001) and have a longer hospital length of stay (5.9 vs. 1.9 days, P<0.0001).

Conclusions: Application of the screening criteria provide a standardized, cost-effective approach for identifying AEs that will complement data collected using other methods. Comparing AEs identified using administrative data with those identified by the voluntary reporting system in the hospital will identify overlap and differences between the approaches to help refine the screening criteria.

Description of Vitamin K Use for Reversing Anticoagulation on Inpatient General Medicine Units
Krista Biederman, Lindsay Blackwell, Eugene Tsai, Natalie Crown
London Health Sciences Centre, London, ON

Rationale: Hospitalization has been associated with poorer anticoagulation control and excessive anticoagulation increases risk of bleeding. The American College of Chest Physicians guidelines outline recommendations for vitamin K use to reverse supratherapeutic international normalized ratios (INRs) in patients receiving warfarin therapy.

Objectives: The purpose of this study was to assess the rate of concordance with guidelines for management of patients with supratherapeutic INRs.

Methods: A retrospective chart review was conducted in patients admitted to general medicine units who received vitamin K for reversal of supratherapeutic INRs or bleeding events from January 1 – December 31, 2009. Patients were identified through pharmacy records and excluded if vitamin K was administered to reverse anticoagulation prior to an invasive procedure. Dose and route of vitamin K were assessed for concordance with guidelines based on the INR and the presence of bleeding prior to administration. The presence of bleeding was categorized as major or minor using definitions from the literature. Descriptive statistics were used to report the data.

Results: Over the one year period, 164 vitamin K administrations were included for 112 patients. Overall, 48% of vitamin K administrations were concordant with guidelines. The rates of concordance for first administrations were 59% for INRs of 5 to 9 without bleeding, 33% for INRs>9 without bleeding, 91% for minor bleeding, and 42% for major bleeding. Fifteen doses of vitamin K were given for supratherapeutic INRs<5 without bleeding. Reasons for discordance with guidelines include unnecessary administration (12.2%), inappropriate dose (29.9%), inappropriate route (21.3%), and repeat doses given too early (3.7%).

Conclusion: Overall adherence to guidelines is low. Vitamin K administration practices can be improved by reducing unnecessary administration, avoiding subcutaneous and intramuscular routes, and by dosing more aggressively for major bleeding events.

Development of a Home Intravenous Inotrope Program for End-Stage Heart Failure Patients
Dustin Chua, Arvinder Buttar, Annemarie Kaan, Holly Andreus, Stephanie Lam
Department of Pharmacy, St. Paul’s Hospital, Vancouver, BC

Rationale: Heart failure (HF) is associated with high morbidity and mortality and is a common reason for emergency department admission. Patients with advanced HF are commonly admitted for inotrope support and heart transplantation is an option for end-stage HF. An intravenous inotrope program was developed.

Description of Service: The SPH HF inotrope program secured funding from the British Columbia provincial drug and palliative care program to cover the cost of the outpatient inotropic drug, ambulatory infusion pump rental and related supplies. Patient eligibility criteria and educational requirements for enrollment in the home inotrope program were developed.

Evaluation: From 2005-2008, 6 patients were enrolled in the SPH home inotrope program. The average duration of outpatient home inotrope therapy was 41 days. Five of the 6 patients eventually received successful heart transplantation and 1 was successfully weaned off inotrope therapy. Two patients were readmitted during home inotrope therapy and no patients experienced arrhythmias requiring hospitalization. The SPH home inotrope program provided significant cost savings to the hospital and health care system (monthly hospital cost = $45,000 versus monthly home inotrope program cost = $4,800 per patient).

Importance to Practice: Home inotrope therapy is a viable option for end-stage HF patients while awaiting heart transplantation and is cost efficient.

PPC 2011 POSTER ABSTRACTS / RÉSUMÉS DES AFFICHES DE LA CPP 2011

CJHP – Vol. 64, No. 1 – January–February 2011
J CPH – Vol. 64, n° 1 – janvier–février 2011
An Analysis of QTc prolonging medication orders belonging to Intensive and cardiac care unit Patients with Pre-existing QTc Prolongation (QTIPPP Study)
Sayako Yokoyama1, Damen Mar1, Vincent H Mahas1, John Martyn1
1Royal Columbian Hospital, New Westminster, BC
2Burnaby Hospital, Burnaby, BC

Rationale: A prolonged QTc interval on the electrocardiogram (ECG) is often used as a surrogate marker for development of ventricular arrhythmias. Medications that can prolong the QTc interval can increase the risk for cardiac complications, although the exact incidence is largely unknown and is multifactorial. However, it is reasonable to consider that administration of QTc prolonging medications to patients who already have a prolonged QTc will further increase their risk of developing cardiac consequences. This study was designed to examine the occurrence of these scenarios and explore the potential role for clinical pharmacist involvement to minimize such risks.

Objective: The primary objective was to identify the number of patients who have a pre-existing prolonged QTc out of all patients who are ordered QTc prolonging medications. Secondary objectives included observing patterns of clinical pharmacist intervention for patients who were ordered QTc prolonging medications. Additionally, any further QTc prolongation and development of cardiac events in the population of interest were documented.

Methods: An observational, prospective, quality assessment study was conducted over four months. Patients included were adults admitted to cardiac monitored beds, who were ordered one or more QTc prolonging medication(s) and had a QTc of >450msec on the most recent 12-lead ECG prior to the medication order.

Results: Two hundred and seven patients were identified as having a QTc prolonging medication ordered. Fifty-three (26%) of these patients had a pre-existing prolonged QTc. Fifty one (25%) of patients received minimum one dose of QTc prolonging medication, and were monitored daily for complications. Nine (18%) of daily monitored patients experienced at least one cardiac event.

Conclusion: Twenty-six percent of patients who were ordered QTc prolonging medications had a pre-existing prolonged QTc interval, suggesting a role for clinical pharmacists’ involvement in reducing risk of subsequent complications.

Development and Validation of Limited Sampling Strategies for Tacrolimus and Mycophenolate in Steroid-Free Renal Transplant Regimens
Eric Poulin1, Erica D Greaney2, Nilafar Parnoo3, R Jean Shapiro4, Mai Al-Khatib5, Mary H H E nsom6
1Vancouver Coastal Health/Providence Healthcare, Vancouver, BC
2Vancouver Coastal Health Authority, Vancouver, BC
3Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC
4Vancouver General Hospital, Vancouver, BC
5Faculty of Medicine, University of British Columbia, Vancouver, BC
6Childrens and Women’s Health Centre of British Columbia, Vancouver, BC

Rationale: Little is known about the clinical impact of steroid withdrawal on the disposition of mainstay immunosuppressive agents such as tacrolimus (TAC) and mycophenolate mofetil (MMF).

Purpose: (1) Develop and validate limited sampling strategies (LSSs) for tacrolimus (TAC) and mycophenolic acid (MPA) in a renal transplant population not receiving corticosteroids; (2) Evaluate predictive performance of published LSSs (for steroid-based regimens) in our renal transplant population.

Methods: Following written informed consent and upon administration of steady-state morning TAC and mycophenolate mofetil doses, blood samples were collected at 0,0.5,1,2,4,6,8,10, and 12h from 28 stable renal transplant recipients; concentrations were measured by validated high-performance liquid chromatography methods and area-under-the-curve (AUC) by trapezoidal method. TAC LSSs were developed and validated via multiple regression analysis (MRA) using the 2-group method (index n=18;validation n=10) and MPA LSSs using the jackknife method (n=28). Potential LSSs were restricted to ones having r²≥0.8 (TAC) or r²≥0.7 (MPA) and <3 time points within 2h (TAC) or 4h (MPA) post-dose. Derived equations were validated for predictive performance, with preset criteria for bias and precision of within ±15%. Other TAC and MPA LSSs were tested using our data.

Results: For TAC, three 3-concentration, one 2-concentration, and one 1-concentration model using concentrations from 0-2h met pre-specified criteria. The best equations were: TAC AUC=10.338+7.739C0+3.589C2 (r²=0.956, bias=-3.37%,precision=4.65%) and TAC AUC=29.479+5.016C2 (r²=0.862,bias=3.15%,precision=9.72%). For MPA, only one model identified for MPA met pre-specified criteria: MPA AUC=9.328+1.311C1+1.455C2+2.901C4 (r²=0.838,bias=-3.78%,precision=14.89). One published TAC (and no MPA) LSS in renal transplant recipients on steroid-based regimens met preset criteria for bias and precision. MPA LSS was not considered for the steroid-free regimen and was not predictive for our steroid-free patients. Corticosteroids may have an impact on predictive performance of MPA LSSs. These hypotheses-generating results warrant further study.

Effectiveness and Safety of an Electrolyte Replacement Protocol in Critical Care Settings
Ann Leung1, Heather Kertland2
1St. Michael’s Hospital, Toronto, ON
2Leslie Dan Faculty of Pharmacy, Toronto, ON

Rationale: To correct electrolyte abnormalities, an electrolyte replacement protocol is utilized in the Medical Surgical Intensive Care Unit (MSICU) and Trauma and Neurosurgery Intensive Care Unit (TNICU) at St. Michael’s Hospital, Toronto, Ontario. The objectives of this study were to measure the effectiveness and safety of the protocol, and to identify areas for improvement.

Methods: The charts of 120 patients who received at least one protocol-directed replacement dose of potassium, calcium, magnesium or phosphorus, and who did not have additional physician orders related to electrolyte replacement were reviewed retrospectively. For effectiveness, data were collected to assess the time, total dose, and number of doses required to return a low serum electrolyte concentration to target range. The occurrence of critically low or high concentrations resulting from protocol-directed replacement was measured as an indicator of safety. Staff compliance to the protocol was also explored.

Results: The average electrolyte concentration requiring replacement was 3.5±0.2mmol/L for potassium, 1.9±0.7mmol/L for corrected calcium, 0.6±0.06mmol/L for magnesium, and 0.5±0.07mmol/L for phosphorus. The median time to return to target range was 9.9 hours to 18.1 hours, depending on the electrolyte. Overall, 77.5% of patients achieved target concentration after one replacement dose. The lowest rate of normalization after one dose was observed for potassium (56.7%). A higher dose was necessary for the replacement of lower
serum concentrations of potassium, magnesium, and phosphorus. The use of the protocol did not result in critical electrolyte concentrations. The overall staff compliance rate was 77.9%, with the lowest compliance observed for timing of follow-up electrolyte concentration measurement.

Conclusion: The electrolyte replacement protocol was safe, and effective for correcting mild to moderate electrolyte deficiencies. Areas for development were identified, including the need for concentration-dependent dosing and reconsideration of follow-up instructions to limit blood collection for only clinically appropriate situations.

Antimicrobial Use in a Critical Care Unit: A Prospective Observational Study

Christina Candeloro1, Lynne Kelly1, Anne Marie Bombasaro1, Elle Bohdanowicz1, Claudio Martin1,2

1London Health Sciences Centre, London, ON
2Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON

Rationale: Antimicrobial use, pathogens, and infections are unique among individual intensive care unit (ICU) settings. Unit specific data guides therapy and stewardship efforts.

Objectives: The study purpose was to describe antimicrobial utilization, modifications, infections and resistance in a medical-surgical-trauma ICU of a tertiary care teaching hospital. The results will guide future stewardship initiatives.

Methods: This was a prospective observational study of adults admitted to the ICU over 30 consecutive days. Exclusion criteria were ICU stay <24 hours and no antimicrobials prescribed. Patients were followed until 30 days post-ICU admission, discontinuation of antimicrobials, transfer from ICU or death. Primary endpoints included percent use of antimicrobials, consumption measured as days of therapy per 1000 patient days (DOT/1000PD), indications for use and prescribing service. Secondary endpoints included reasons for and timing of therapy modifications and microbial resistance. Data analysis was descriptive.

Results: Eighty-three patients were screened and 61 enrolled, receiving 133 courses of antimicrobial therapy mainly prescribed by ICU staff. The most frequently prescribed agents were piperacillin-tazobactam (27%), ceftazolin (22%) and vancomycin (17%). The indications for therapy were empiric (50%), directed (27%) and prophylactic (23%). Overall consumption was 1368 DOT/1000PD with empiric, directed and prophylactic therapy accounting for 734, 454 and 180 respectively. Consumption exceeded frequency of use only for the carbapenem class of antibiotics (14% versus 8%). There were 86 therapy modifications involving indication (36), efficacy (25), safety (18) and route (7). Suboptimal dosing of piperacillin-tazobactam and vancomycin was the major contributor to efficacy modifications. Median time from a culture report to therapy modification was 2.77h (range 0.23 to 72.2h). Notable micro-organism resistance included methicillin resistant S. aureus, vancomycin resistant enterococcus, P. aeruginosa and S. pneumonia.

Conclusions: Piperacillin-tazobactam was the most frequently prescribed antimicrobial. Targets for stewardship initiatives include empiric therapy, prolonged carbapenem courses and optimization of piperacillin-tazobactam and vancomycin doses.

Mood Elevation and Pain Control with Duloxetine Monotherapy in Multiple Sclerosis

Sarah Burgess1, Joel Lamoure2, Jessica Stovel2

1London Health Sciences Centre, London, ON
2University of Western Ontario, London, ON

Rationale: AMultiple sclerosis (MS) is a devastating disease that manifests with demyelination and lesion development in the brain and spinal cord. MS impacts patient functionality and quality of life on a number of facets, including mood and pain, which are strongly linked.

Case Description: A 36-year-old female presented in 1996 with a cervical lesion suggestive of early MS. The patient developed four new cervical lesions and was subsequently diagnosed with definite MS in April 2010. The patient was also diagnosed with generalized anxiety disorder, panic attacks and self-reported elevated alcohol use. Trials of citalopram and venlafaxine were conducted unsuccessfully. Paroxetine therapy was initiated and titrated gradually to 17.5mg/day in the spring of 2010 to address her mood and anxiety. The patient developed neurological symptoms at this time, including neck and bilateral upper extremity pain with right-sided hemiparetic attacks, suggestive of L’Hermitte’s. As the paroxetine dose increased, the patient experienced anhedonia, alopecia, worsening pain and reduction in libido. Paroxetine was subsequently discontinued and duloxetine initiated at 30 mg daily through cross tapering. Three weeks after paroxetine discontinuation, pain diaries and scales reflected lessened pain while the L’Hermitte’s continued. Mood and anxiety improved and duloxetine subsequently was increased to 60mg daily.

Evaluation of the Literature: The clinical efficacy of duloxetine for the treatment of major depression and generalized anxiety disorder is well established. Evidence exists for duloxetine in diabetic peripheral neuropathy and fibromyalgia patients to control pain. Published literature examining the use of duloxetine for pain management, mood elevation and control of anxiety in MS patients is lacking.

Importance to Pharmacy Practitioners: Duloxetine lessened anxiety and pain, improved mood thus resulting in enhanced quality of life in this case. Further studies may be warranted in MS patients with pain and psychiatric co-morbidities.
Proton Pump Inhibitor Use among Seniors on Public Drug Programs, 2001 to 2008

M. Gaucher, J Hunt
Canadian Institute for Health Information, Ottawa, ON

Rationale: Acid-related diseases of the gastrointestinal system affect an estimated 29% of Canadian adults. Two drug classes, proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly used to prevent and treat these conditions. PPIs have shown improved efficacy over H2RAs, and are generally considered to be safer medications with few adverse effects. However, there have been increasing concerns regarding adverse effects associated with long-term and high-dose PPI use.

Objective: To compare PPI use to that of H2RAs and break down use by age and sex. Also, to explore the influence PPI dosages and length of therapy may be having on the overall trend in PPI use.

Methods: This study examined claims for 1,103,098 seniors on public drug programs in Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia and PEI between 2001-2002 and 2007-2008. Drug classes were defined using the World Health Organization’s Anatomical Therapeutic Chemical classifications.

Results: The age–sex standardized rate of PPI use among seniors on public drug programs increased from 13.1% in 2001–2002, to 21.1% in 2007–2008. During the same time period, H2RA use fell from 12.7% to 8.8%. The average daily dose of PPIs used by seniors on public drug programs remained relatively stable, with roughly 80% of PPI claimants using an average daily dose within the standard dosage range each year. The rate of chronic PPI use increased, with 65.8% of seniors taking PPIs considered to be chronic users in 2007-2008.

Conclusions: There was a significant increase in the use of PPIs among seniors on public drug programs in Canada, which coincided with a decrease in H2RA use. Although the average daily dose of PPIs used by these seniors did not increase during the study period, a higher proportion of seniors were taking PPIs for longer periods of time.
Results: The final dataset included 9,944 adults aged 18 and older. The percentage of respondents who reported having experienced a medication error ranged from 7.5% in Australia to 26.5% in Canada. Risk factors for a self-reported medication error are: taking between 6-10 medications (p<0.05) and more than ten medications (p<0.0001), female gender (p<0.05), age 50-64 (p<0.01) and not having a regular doctor (p<0.05). The risk factors for an increased occurrence of medication errors in hospital include taking between 6-10 medications (p<0.0002) and age 25-34 (p<0.005). Females are at a higher risk of experience a medication error in the community setting (p<0.03).

Conclusions: Through the use of a large survey database across multiple countries, this study has identified the risk factors of a self-reported medication error in the hospital setting, community setting and in both settings combined. Based on the findings of this study, strategies could be developed and targeted to one or more of the identified risk factors.

Adverse Events Related to Medications Identified by a Canadian Poison Centre

Stacy Ackroyd-Stolarz1, Neil J MacKinnor1, Nancy Murphy1, Eileen Gillespie2, Peter Zed2
1Department of Emergency Medicine, Queen Elizabeth II Health Sciences Centre, Halifax, NS
2College of Pharmacy, Dalhousie University, Halifax, NS

Rationale: Poison Centres are an untapped source of information on adverse events related to medications, including therapeutic errors and adverse drug reactions.

Objective: The objective of this one-year, retrospective cross-sectional pilot study conducted at one Canadian Poison Centre was to demonstrate the feasibility of using their electronic data to identify and describe adverse events related to medications.

Study Design and Methods: All electronic records from the IWK Regional Poison Centre in Nova Scotia between November 1, 2007 and October 31, 2008 for unintentional exposures were abstracted for a descriptive data analysis.

Results: A medication was involved in 1,525 (32.5%) of 4,697 eligible calls. There were 470 (30.8%) calls for unintentional therapeutic errors and 61 (4.0%) for adverse drug reactions; the remainder were coded as ‘unintentional general’ (970 [63.6%]). The latter category included events such as ingestion of an adult’s medication by a young child. A higher proportion of calls involving medications (compared with non-pharmaceutical substances) resulted in a referral to a healthcare facility (10.2% vs. 6.0%, p<0.0001), admission to a non-critical care unit (9.4% vs. 3.9%, p=0.002) or to a critical care unit (2.6% vs. 1.2%, p=0.1).

Conclusions: Poison centres offer an accessible, well-established community resource for individuals and/or healthcare professionals to report adverse events related to medications. Establishment of a mechanism to routinely share information from all Canadian Poison Centres with relevant national drug safety programs will enhance integration of national reporting schemes and the capacity for detection of sentinel events.

Evaluation of the Efficacy and Toxicity of Once-Daily Gentamicin for Febrile Neutropenia in Pediatric Oncology Patients

Emilie Lavensant1,2, Tejinder Bain3, Régis Vaillancourt2, Genevieve Goulet1, Jane Hiliard1, Elena Pacuce1, Jacqueline Halton1
1University of Claude Bernard Lyon 1, France (pharmacy student)
2Department of Pharmacy, Children’s Hospital of Eastern Ontario, Ottawa, ON
3Division Pediatric Hematology/Oncology, Children’s Hospital of Eastern Ontario, Ottawa, ON

Rationale: Once daily gentamicin in combination with piperacillin is the empirical treatment used for pediatric neutropenic fevers at our institution. However, literature evaluating the efficacy and toxicity of this therapeutic combination remains scarce.

Objective: To assess efficacy and toxicity of once daily dosing of gentamicin as a component of the empirical antibiotic treatment for febrile neutropenia.

Study Design and Methods: Retrospective review of pediatric oncology patients with admitting diagnosis of febrile neutropenia between January 1, 2005 and December 31, 2008. Clinical efficacy assessed by success of treatment in achieving symptomatic recovery without any modification to the initial therapy. Theoretical efficacy determined by classifying febrile episodes into groups: 1) clinically documented infection (CDI); 2) microbiologically documented infection (MDI); or 3) fever of unknown origin (FUO). Responses to treatment identified as follows: complete and early response (<3 days) to the initial treatment, later response to the initial treatment with or without the addition of antifungals or antivirals, and failure of the initial therapy defined as a change of antibiotic therapy. Renal toxicity and ototoxicity also assessed.

Results: 168 patient charts reviewed, which included 280 episodes of febrile neutropenia. In terms of clinical efficacy, 16.1% of attempted treatments failed and led to a modification of the antibiotic therapy. In terms of theoretical efficacy, 63.2% of episodes responded completely and rapidly to the gentamicin-piperacillin regimen, 17.1% had a partial and delayed response, and 19.7% failed therapy. Nephrotoxicity observed in 3.9% of episodes (n=11). In 54.5% of these cases of nephrotoxicity, patients had also received vancomycin. Audiology tests were available for 9 patients, of which 44.4% (n=4) had abnormal results.

Conclusion: Empirical treatment with once daily gentamicin in combination with piperacillin in neutropenic fevers is effective and safe. Gentamicin was not responsible for deterioration of renal function when regular monitoring completed.

Encore Presentation

Optimization of Medication Reconciliation on Admission for Pediatric Inpatients

Elaine Wong, Régis Vaillancourt, Pierre Katz
Children’s Hospital of Eastern Ontario, Ottawa, ON

Rationale: Medication reconciliation (MR) is a process designed to provide the most complete and accurate list possible of all medications during transfer of care. The pharmacy department is reviewing the existing MR process completed by a team of Pharmacy Assistants (PAs) to optimize patient care and capture all inpatient admissions.

Description of Concept: At its conception, MR was performed by a single PA. However, the process is now supported by a team of 4 PAs 7 days a week. In an effort to harmonize the MR process, the process is being reviewed to establish best practice and improve the ability to...
Étude pilote sur la surveillance environnementale en pharmacie communautaire

Jean-François Bussières1, Cynthia Tanguay1, Alain Soulard2, Michel Lefèvre3, Éric Langlois3
1CHU Sainte-Justine, Montréal, QC
2Centre de santé et de services sociaux de la Vérone-Capitale, Québec, QC
3CTQINSPIQ – Centre de toxicologie du Québec / Institut national de santé publique du Québec, Québec, QC

Introduction: Il existe un risque pour les médicaments utilisés en pharmacie communautaire. Un médicament dangereux possède au moins l'une des caractéristiques suivantes: cancérigène, mutagène, tératogène, toxique pour un organe ou pour la reproduction. Il n'existe pas de seuil acceptable de contamination environnementale aux médicaments dangereux.

Objectifs: Évaluer la contamination environnementale aux médicaments dangereux en pharmacie communautaire.

Méthodologie: Il s'agit d'une étude pilote descriptive de la contamination de surface de médicaments dangereux (c.-à-d. métotrexate, cyclophosphamide et ifosfamide) à partir d'un échantillonnage de convenances de huit pharmacies communautaires volontaires au Québec en 2009-2010. Aucune statistique n'a été réalisée et seules des données descriptives sont présentées.

Résultats: Au sein des huit pharmacies communautaires de l'étude, un total de 44 prélèvements, provenant de 3 à 8 sites distincts de mesure par pharmacie, a été effectué et analysé. L'étude indique que 27% (12/44) des prélèvements sont positifs pour le métotrexate (médiane 3,2 ng/cm² [0,03-48]). Aucune trace n'a été détectée pour le cyclophosphamide et l'ifosfamide. Des 12 prélèvements positifs, 7 proviennent du compte-pilule, 4 des tablettes de rangement et un de la surface extérieure d'un contenant. Pour une seule pharmacie, aucune trace de médicaments dangereux n'a été retrouvée. La présence de traces sur l'extérieur d'un contenant de métotrexate rappelle l'importance du port de gant.

Conclusion: Cette étude pilote démontre qu'on peut retrouver des traces de médicaments dangereux de métotrexate dans les pharmacies communautaires, suggérant un entretien insuffisant des compte-pilules et autres espaces de rangement. La diffusion de ces résultats peut contribuer à rehausser le niveau de vigilance et de conformité aux lignes directrices entourant la manipulation de médicaments dangereux en pharmacie communautaire. Cette étude pilote précède une étude à plus large échelle qui sera effectuée en 2011 en pharmacie communautaire au Québec.
Objectifs : Décrire le profil des ruptures d’approvisionnement de médicaments en établissement de santé. 
Conclusion : Il existe peu de données sur les ruptures d’approvisionnement en médicaments en établissement de santé. Ces données confirment une augmentation de la problématique.

Développement d’une approche web peu coûteuse pour la formation continue intra-hospitalière

Gabrielle Ferland1, Isabelle Goyer1, Denis Lebel1, Jean-François Busiéri1,2
1CHU Sainte-Justine, Montréal, QC
2Faculté de pharmacie, Université de Montréal, Montréal, QC

Justification : La prestation sécuritaire repose sur un maintien de la compétence des professionnels. Il est difficile d’assurer la formation continue des professionnels compte tenu de la pénurie de ressources humaines et financières. La mise à niveau du circuit du médicament en établissement de santé amène l’introduction de nombreux changements et technologies.

Description du concept : Il s’agit d’un concept de développement d’une approche web peu coûteuse pour la formation continue intra-hospitalière.

Mesures prises : À partir d’une revue documentaire, nous avons identifié les différentes approches de scénarisation, de production et de diffusion de contenus pouvant être utilisées pour la formation continue. Nous avons développé une séquence optimale des étapes devant mener à la création de power-point dynamique intégré sous forme de vidéos Web à partir du logiciel Camtasia® (~ 200 $ pour une licence académique). Ainsi, une vingtaine de productions web variant de 5 à 12 minutes ont été développées (~ 24 heures de travail par production ~ 500$/production) et utilisées dans le cadre du circuit du médicament (p.ex. implantation de nouveaux chariots unidose, déploiement d’un logiciel de gestion des préparations avec code-barres, présentation de l’intranet pharmacie, utilisation du dossier pharmacologique informatisé, utilisation des caméras pour la numérisation des pratiques de préparation). Toutes les productions sont publiées sur l’intranet et peuvent être visionnées par les professionnels en tout temps.

Évaluation du projet : Notre démarche confirme la faisabilité d’une approche web peu coûteuse. Elle a permis la formation de plusieurs centaines de professionnels. La prochaine étape consiste à développer les outils permettant le monitoring et la documentation du visionnement et de l’auto-évaluation des apprentissages.

Utilité du concept : Le partage d’expériences pratiques permettant la scénarisation, la production et la diffusion de contenus est nécessaire afin de permettre à un plus grand nombre d’établissements d’optimiser leur formation continue.

Impact of a Debate on Pharmacy Students’ Views of Online Pharmacy Practice

Jean-François Busiéri1,2, Anais Delicourt1, Nedjma Belaid3, Marie-Pierre Quirion1, Julien Desrocher1, Josiane Bégin1, Anne-Marie Pragasi1, Diane Lamarre2
1CHU Sainte-Justine, Montréal, QC
2Faculté de pharmacie, Université de Montréal, Montréal, QC

Rationale: Few data have been collected on the use of debates as part of healthcare professional training.

Objectives: To describe the impact of a debate on how pharmacy students feel about online (ie, Web-based) pharmacy practice.

Study Design: This is a quasi-experimental interrupted time-series study (pre-phase, post-phase 1 and post-phase 2). A 60-minute debate about online pharmacy practice was organized as part of a lunchtime conference. The students were asked to complete an evaluation questionnaire (four-category Likert scale) in the pre-phase (ie, before the debate) and post-phase 1 (ie, after the debate) and post-phase 2 (ie, six months after the debate). A total of 177 students volunteered to take part in the debate. A 100% response rate in the pre-phase and post-phase 1 was noted, but only 31% in post-phase 2. We calculated the proportion of the respondents who agreed with each of the statements and the proportion of the respondents in favor of online pharmacy practice.

Results: The respondents’ support for the use of online pharmacy showed little variation, namely 30%±22% in the pre-phase, 33%±23% in post-phase 1 and 29%±24% in post-phase 2. The average proportion of respondents who changed their opinion was 43%±8%; 21%±7% of the respondents reversed their opinion, 22%±4% nuanced their opinion and 1%±1% changed radically their opinion. Respectively 98% (post-phase 1) and 96% (post-phase 2) of the respondents were of the opinion that debate was a very useful teaching formula in their pharmacist training and 79% and 66% thought debate significantly changed their opinion of the issue.

Conclusion: These results suggest that debate can contribute to critical thinking. Students appreciated using debates as a teaching formula and considered that the approach was very useful in their pharmacist training, particularly when it concerned a controversial issue. Pharmacists should consider integrating more debates in their teaching approaches.
Evolution of Prescription Patterns for Acute Otitis Media in Children at the Emergency Department

M-J Vilemues, L Bergeron, C Guimont
CHUL (CHUQ), Québec, Québec

Background: Acute otitis media (AOM) is the most common reason for both antibiotic use in children and emergency visits at the CHUL, a regional pediatric referral center. A study was performed in 2006 to describe the treatment of AOM in our emergency department (ED). We did a follow-up study in 2008 and compared the results with those obtained in 2006 and with the provincial guidelines for treatment of AOM published in 2005.

Methods: Medical records of children < 6 years old seen at the ED, and discharged with a diagnosis of AOM between November 2008 and February 2009 were reviewed. The results were compared with the findings of our previous study done in 2006.

Results: We included 195 medical records in the analysis, accounting for 197 prescriptions. The previous study in 2006 included 192 prescriptions. Wait-and-see approach (WASP) was used for only 5.6% of the children in 2008, compared with 10.4% in 2006. When an antibiotic treatment was prescribed, amoxicillin was the agent chosen for 78.5% of children, compared with 61.0% in 2006. Among prescriptions of amoxicillin or amoxicillin-clavulanic acid, high-dose (80-90 mg/kg/day) was regularly prescribed (137/174; 78.7%) as was the case in 2006 (86/118; 72.9%). The conformity with guidelines for antibacterial agent choice, dose, dosing interval and duration of therapy improved compared to 2006 (16.6%, 16.6%, 8.8%, and 15.4% improvement, respectively; p<0.007). However, treatment duration remained generally longer than recommended (76.1% conformity rate). In children > 2 years old, a 10-day treatment was still frequently prescribed (37.3%), instead of the recommended 5 to 7-day treatment (41.3%).

Conclusions: WASP remains scarcely used. Global conformity of AOM prescriptions improved, possibly as a result of presentation of the 2006 study findings and better ED physician knowledge of provincial guidelines.

Development of a Diary for Use by Children to Record their Chemotherapy-Induced Nausea and Vomiting Experience

S R lavatore, M Linneman, A M Maloney, P C Nathan, T Taylor, E Zelunka, L L Dupuis
The Hospital for Sick Children, Toronto, ON

Rationale: To conduct investigations regarding chemotherapy-induced nausea and vomiting (CINV) control in children with cancer, a diary for recording nausea and vomiting severity is required.

Objective: To develop a diary for children to describe their CINV experience and determine its face validity.

Study Design and Methods: A draft diary and instruction sheet were developed which incorporated the Pediatric Nausea Assessment Tool (PeNAT), a validated nausea severity assessment tool. Five pediatric oncology nurses assessed the draft diary’s readability and face validity; their opinions were solicited using a standard questionnaire administered in a face-to-face interview. The documents were revised based on this feedback. Five patients who received highly emetogenic chemotherapy and their families used the diary to record the severity of their nausea and vomiting and the antiemetics used on each day chemotherapy was given and for seven days afterwards. The patients and their guardian(s) opinions were solicited in a face-to-face interview once the diary was completed. Revisions to the diary were made accordingly.

Results: The nurses believed that patients/families would find the diary easy to use. Changes made based on the nurses feedback included incorporating more check boxes and separating times nausea severity are to be recorded. Patients and their families also found the diary easy to use and reported completing the diary took a median of 2.5 minutes daily (range 1-10 minutes), 39 (83%) of the expected diary pages were completed and returned. Changes made to the diary based on patient/family feedback included placing the PeNAT faces on the back of the diary.

Conclusion: A diary was developed for pediatric patients to describe their CINV experience that was understandable and easy to use. This diary will be used during observational and intervention trails of CINV in children with cancer.
Point Prevalence Survey of Antimicrobial Utilization in the Cardiac and Paediatric Critical Care Unit

Ekatrina Bliinova1, Winnie Seto1,2, Elaine Lau1, Ari Bitoun2, Peter Coo1, Steven Schwarze1, Eshetu Ateneff1, Yvonne Yiu1, Laurie Streitenberger1, John Marshall1, Christopher S Parshuram1
1Department of Pharmacy, 2Child Health Evaluative Sciences, 3Division of Infectious Disease, 4Cardiac Critical Care Medicine, 5Paediatric Laboratory Medicine, 6Infection Prevention & Control, 7The Hospital for Sick Children, Toronto, ON
8Laurie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON
9Critical Care Medicine Research, St Michael's Hospital, Toronto, ON

Rationale: Definitive diagnosis of infection in critically ill children is difficult and antimicrobials are often prescribed empirically. This creates challenges for appropriate antimicrobial use.

Objectives: To determine the rate of documented infections and prevalence of antimicrobial use among patients admitted to the Cardiac and Medical-Surgical Critical Care Units (CCCU – PICU) at SickKids®. To assess the appropriateness of antimicrobial prescribing according to clinical and microbiological findings. Infectious Diseases consult recommendations, and formulary guidelines.

Study Design and Methods: A prospective point-prevalence study was conducted in the CCCU-PICU of a tertiary care teaching hospital in Toronto. All patients admitted to the CCCU-PICU during the week of October 27, 2008 (Period A) and February 9, 2009 (Period B) were followed until completion of their antimicrobial course(s). Data was collected on infections treated and antimicrobials prescribed. Appropriateness of antimicrobial prescribing was assessed according to pre-defined criteria by 4 blinded assessors.

Results: Forty-two of 60 patients (70%) received antimicrobials in Period A and 42 of 53 patients (79%) received antimicrobials in Period B. Of patients receiving antimicrobials, 45% in Period A and 52% in Period B had a definitive diagnosis of infection. The most common infections were pneumonia and sepsis (Period A) and pneumonia and other respiratory tract infections (Period B). Antibiotics were most commonly prescribed for documented infection (38%) during Period A and empiric therapy (47%) during Period B. Cefazolin, cefuroxime, vancomycin and gentamicin were most commonly prescribed during both periods. Inappropriate antimicrobial use ranged from 16.7% to 61.9%, depending on the assessor and surveillance period. The most common reasons for inappropriate use were wrong dosage, overly-broad spectrum, and unwarranted overlap of spectrum.

Conclusions: There was a high prevalence of antimicrobial use in CCCU-PICU patients. A significant proportion of antimicrobial use was deemed inappropriate, thus interventions are required to optimize antimicrobial use in critically ill children.

Medication Incidents Involving Cancer Chemotherapy Agents

Roger Cheng, Carol Lee, Sylvia Hyland, John Senders, Certina Ho
Institute for Safe Medication Practices Canada, Toronto, ON

Rationale: Cancer chemotherapy agents are considered “high-alert” medications with inherent heightened risk of causing significant patient harm when associated with a medication incident. It is therefore imperative to evaluate current chemotherapy practices and derive system-based safeguards to optimize patient safety. One way of achieving this purpose is via an analysis of medication incidents involving chemotherapy.

Description: Medication incidents reported between 2002 and 2009 involving chemotherapy were extracted from the ISMP Canada medication incident database. A quantitative analysis was conducted to provide an overview of various trends such as the severity of outcome. A qualitative analysis was conducted with the subset of incidents containing sufficient narrative descriptions to identify recurrent themes and contributing factors.

Evaluation: A total of 519 incidents were included in the quantitative analysis. Of these incidents, 40 (7.7%) had an outcome of harm, and 4 (0.8%) had an outcome of death. Nearly 90% of these reports (n=456) contained sufficient narrative descriptions and were included in the qualitative analysis. The qualitative analysis revealed 7 main themes; each theme reflects a high-level process within the medication-use system common to the provision of cancer chemotherapy in most patient care settings. They include: 1) scheduling the patient’s visit to...
Identification of Medication Safety Indicators in Acute Care Settings for Public Reporting In Ontario

Roger Cheng, Lindsay Yoo, Certina Ho, Medina Kadiza
Institute for Safe Medication Practices Canada, Toronto, ON

Rationale: In healthcare settings, indicators are useful tools for assessing the structure, process, and outcomes of patient care. Moreover, when used for public reporting, indicators can offer greater transparency of our healthcare system. The objective of this study is to identify three medication safety indicators in acute care settings for public reporting in Ontario.

Description and Steps Taken: A multi-phase process was developed for this project. This included a systematic literature review, compilation and evaluation of possible medication safety indicators, and a consensus generation process (modified nominal group technique) involving a group of 17 Ontario healthcare experts from various disciplines.

Evaluation: More than 300 medication safety indicators were identified through the systematic literature review. Two analysts, working independently and using a defined set of selection criteria, selected 49, and subsequently narrowed to 12 candidate indicators, which were then presented to a group of leading practitioners across the healthcare fields in Ontario. The group reached consensus on three medication safety indicators, which focused on the areas of venous thromboembolism prevention, discharge medications of acute myocardial infarction, and medication reconciliation.

Conclusions: This report describes a systematic process undertaken by ISMP Canada to identify three medication safety indicators in acute care settings for public reporting in Ontario. These indicators refer to important aspects of medication safety at which deficiencies can result in significant patient harm. They can potentially provide hospitals and healthcare providers with tangible and realistic mechanism for measuring performance and, ultimately, improving quality of care.

Encore Presentation

Sustained Cost Savings and Fewer Dose Administration Errors in Hemodialysis Patients Converted from Epoetin Alfa to Darbepoetin Alfa in a Community Hospital Setting

Jessica Jordan, Joanne Breckles, Valerie Leung
Toronto East General Hospital, Toronto, ON

Background/Objectives: In January 2005, the hemodialysis (HD) unit at Toronto East General Hospital switched all patients from IV epoetin alfa (EPO) to IV darbepoetin alfa (DPO). The purpose of this study was to quantify erythropoiesis stimulating agent (ESA) utilization, cost implications and medication administration errors (MAEs) before and after the EPO to DPO switch, as well as to quantify 5 year cost implications.

Methods: The study design was a 15 month retrospective observational study. During this time period, ESA doses were titrated to target hemoglobin and iron indices in accordance with the 2001 NKF-DGQI guidelines. ESA weekly doses and MAEs were collected for 6 months pre-conversion and 9 months post-conversion (3 month titration and 6 month post-conversion period). A follow-up sub-group analysis was performed on patients in the HD program 5 years after conversion for 6 months.

Results: Thirty-seven patients underwent conversion to DPO and the sub-group analysis consisted of 16 patients. During the study, hemoglobin and iron indices were maintained within target range while median DPO dose decreased from 50 to 20mcg (P=0.026, Wilcoxon signed-rank test). Further dose reductions in DPO dose was seen after 5 years (30mcg in 2005 versus 20mcg in 2010, P=0.0006 using Wilcoxon signed-rank test) with an estimated annual cost savings of $3100 per patient. Thirty MAEs were observed after DPO conversion compared to 106 during EPO pre-conversion (P<0.0001, Fisher exact test). Thirty-four patients had at least one or more MAE while on EPO compared to 17 patients after DPO conversion. The absolute risk of a medication discrepancy was reduced by 8% after conversion to DPO.

Conclusion: This real world dosing evaluation study showed continued cost savings after 5 years and fewer medication administration errors when HD patients were switched from EPO to DPO, while maintaining clinical targets.

Revising Automated Dispensing Cabinet Inventory to Improve Efficiency

Sara Kynicos1, Paul Lee2, Jin-Hyeun Hub3, Esther Fung4
1Department of Pharmacy, Toronto Western Hospital, University Health Network, Toronto, ON
2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON (Pharmacy Student)
3Department of Pharmacy, University Health Network, Toronto, ON

Rationale: Many hospitals are increasingly dependent on Automated Dispensing Cabinets (ADCs), to provide a safer, medication delivery system. However supporting this system is labour intensive and unfortunately not all medications may be in ADCs due to capacity restrictions (patient specific medications).

Objectives: The objective was to revise the entire contents of eight ADCs (across three In-Patient units) to determine if this impacts the frequency, quantities of ADC medication refills and accommodate all patient-specific medications without resorting to non-ADC storage (e.g., cassettes)

Methods: An annual drug usage report was generated for each inpatient unit to create a top 300 list. A minimum of 72 hour supply in each ADC of the highest use medications was the target quantity.
Early Impact of a Decentralized Automated Dispensing System in a Small Regional Hospital
Lenard Walser, Jill Skinner, Anne Chisholm
Colchester East Hants Health Authority, Truro, NS

Rationale: Automated drug distribution systems can enhance patient safety, provide cost savings and improve staff satisfaction.

Description: Colchester East Hants Health Authority is a 120 bed community hospital that transformed a centralized drug distribution system to an automated, decentralised unit-dose system in the Spring of 2010. The transition included pharmacy, in-patient, ambulatory, emergency and surgical services. The system included Automated Dispensing Cabinets (ADC), narcotic vault system, electronic order scanning system, medication carousel and unit-dose packager. Barcode scanning is utilized throughout the distribution system and all ADCs are profiled via the Pharmacy Information System except surgical services.

Implementation: Following completion of interface testing, the automation transition occurred over four months.

Evaluation: Three months post implementation, medication-related reportable occurrences decreased by 37% and medication departmental costs decreased by 24% compared to the same period one year earlier. A staff satisfaction survey was completed by 77 respondents, where 1 = strongly disagreed, 3 = no difference and 5 = strongly agreed. Pharmacists valued reduced distribution responsibilities (AVE = 4, SD = 1.0) and increased time for clinical services (AVE = 4, SD = 0.7). Technicians reported enhancements in narcotic security (AVE = 4.1, SD = 0.79), and improved accuracy with barcode selection (AVE = 3.9, SD = 0.99). Nursing valued reduced narcotic counting and ordering of medications (AVE = 4.3, SD = 1.0), increased patient safety (AVE = 3.5, SD = 0.96) and less time searching for medications (AVE = 3.5, SD = 1.02). Nursing did report an increase in medication administration time (AVE = 3.3, SD = 1.07). Overall, when asked if the distribution system was a significant improvement over the previous system, the responses were as follows: pharmacists (AVE = 4.8, SD = 0.45), technicians (AVE = 4.2, SD = 0.72) and nurses (AVE = 3.3, SD = 1.02).